Fibrocell Science, Inc.

( )
FCSC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -5.67%54.440.0%$1450.33m
GILDGilead Sciences, Inc. -0.66%72.701.0%$1278.98m
AMGNAmgen, Inc. 0.04%222.481.3%$637.69m
NVAXNovavax, Inc. 0.27%48.30102.0%$610.31m
REGNRegeneron Pharmaceuticals, Inc. -1.85%535.132.5%$605.59m
VRTXVertex Pharmaceuticals, Inc. -0.28%265.751.9%$514.87m
BIIBBiogen, Inc. 0.98%298.771.6%$417.07m
ILMNIllumina, Inc. 1.75%360.603.5%$360.95m
SRNESorrento Therapeutics, Inc. 1.33%5.341.8%$311.14m
SGENSeattle Genetics, Inc. 0.44%152.396.1%$244.10m
ALXNAlexion Pharmaceuticals, Inc. 0.97%103.802.0%$226.24m
AAgilent Technologies, Inc. 0.87%86.891.6%$197.86m
CODXCo-Diagnostics, Inc. -0.78%17.890.0%$184.49m
MGNXMacroGenics, Inc. -1.44%23.306.2%$175.70m
BMRNBioMarin Pharmaceutical, Inc. 6.39%103.744.3%$172.63m

Company Profile

Fibrocell Science, Inc., is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. The fibroblast cell plays a key role in the production of collagen and growth factors which support the skin and other soft tissues; therefore, these cells could play a key role in treating many medical conditions. They have a robust pipeline and clinical programs based on the autologous fibroblast cell. They believe their aesthetic indication is a beachhead for higher value indications. They have a strong base of knowledge and expertise in cell based product development, manufacturing and seeking regulatory approvals. Their focus is to enter clinical programs to treat medical conditions that have an unmet need, helping patients and creating more value per cell.